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Background:
Endemic  malaria  and  helminth  infections  in sub-Saharan  Africa  can  act as  immunological  modulators  and
impact  responses  to  standard  immunizations.  We conducted  a cohort  study  to  measure  the  inﬂuence of
malaria  and helminth  infections  on  the immunogenicity  of the  bivalent  HPV-16/18  vaccine.
Methods:
We evaluated  the  association  between  malaria  and helminth  infections,  and  HPV-16/18 antibody
responses  among  298  Tanzanian  females  aged  10–25  years  enrolled  in  a randomized  controlled  trial  of  the
HPV-16/18  vaccine.  Malaria  parasitaemia  was  diagnosed  by  examination  of  blood  smears,  and  helminth
infections  were  diagnosed  by  examination  of  urine  and  stool  samples,  respectively.  Geometric  mean
antibody  titres  (GMT)  against  HPV-16/18  antibodies  were  measured  by  enzyme-linked  immunosorbent
assay.
Results:
Parasitic  infections  were  common;  one-third  (30.4%)  of participants  had  a helminth  infection  and  10.2%
had  malaria  parasitaemia.  Overall,  the vaccine  induced  high  HPV-16/18  GMTs,  and  there  was  no  evidence
of  a reduction  in  HPV-16  or HPV-18  GMT  at  Month  7 or Month  12  follow-up  visits  among  participants
with  helminths  or malaria.  There  was  some  evidence  that  participants  with  malaria  had  increased  GMTs
compared  to those  without  malaria.
Conclusions:
The data  show  high  HPV  immu
The  mechanism  and  signiﬁcan
          
 This  study was  registered under ControlledTrials.com (ISRCTN90378590).
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ce  for the  increase  in  GMT  in those  with  malaria  is  unknown.
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. Introduction
Human papillomavirus (HPV) genotypes 16 and 18 are esti-
ated to cause 70% of cervical cancers worldwide [1]. Over 85% of
he global burden of cervical cancer occurs in developing countries
nd Tanzania reports one of highest rates of cervical cancer in Africa
2]. Potent, durable HPV vaccine efﬁcacy will be essential if the
accine is introduced for the control of cervical cancer. Endemic
nfections in sub-Saharan Africa, such as malaria and helminth
nfections, act as immunological modulators, and have been found
o adversely impact immune response to standard immunizations,
uch as antituberculosis vaccine bacillus Calmette–Guerin (BCG),
yphoid fever, tetanus and polio vaccines [3–9]. Studies to evalu-
te the effect of HPV vaccines in populations whose immunological
ystem may  be challenged by multiple co-infections such as malaria
nd helminth infections are needed [10,11]. We  conducted a study
o measure the inﬂuence of malaria parasitaemia and helminth
nfection on the immunogenicity of HPV-16/18 vaccine (Glaxo-
mithKline (GSK) Biologicals SA). This study was nested within a
ohort recruited for a Phase IIIb immunogenicity and safety trial
f the HPV-16/18 vaccine (the HPV 021 trial) conducted in Tanza-
ia and Senegal among HIV-negative girls and young women  aged
0–25 years [12].
.  Methods
The HPV 021 trial (NCT00481767) and the malaria/helminth
tudy were conducted from October 2007 to July 2010 in Mwanza,
anzania, one of the two participating HPV-021 trial centres. GSK
iologicals was the funding source for the studies. Both studies
ere approved by the ethics committees of the National Insti-
ute for Medical Research (NIMR), Tanzania and the London School
f Hygiene & Tropical Medicine (LSHTM), United Kingdom. The
elminth/malaria study was registered under ControlledTrials.com
ISRCTN90378590).
The HPV 021 trial was a double-blind, randomized, placebo-
ontrolled phase IIIb trial. Eligible participants were randomly
ssigned (2:1) to receive either three doses of HPV-16/18 AS04-
djuvanted vaccine (vaccine group) or Al(OH)3 (placebo group) at
,1 and 6 months. After enrolment (Month 0), participants returned
o the clinic at Months 1, 2, 4, 6, 7, 8, 10 and 12 for follow-up
isit procedures. Participants were tested for malaria and helminth
nfections at the Month 7 visit, one month after the scheduled
accine dose 3. In addition, participants could attend government
ealth services for investigation and management of any illnesses
etween booked study visits. A record was kept of investigations
nd treatments given through these other health services.
The  primary objective of this analysis was to evaluate the associ-
tion of malaria parasitaemia and helminth infection with antibody
esponses against HPV-16 and HPV-18 one month (Month 7) and six
onths (Month 12) after the last scheduled vaccine dose in African
emales aged 10–25 years.
Potential  participants were recruited from schools, colleges and
amily planning clinics in Mwanza, and invited to attend a screening
isit for eligibility approximately one month prior to enrolment.
rior to screening, informed consent was obtained from partic-
pants aged 18–25 years. For participants aged 10–17 years, we
ought consent from a parent or legally authorized representative,
s well as assent from the participant. Participants were eligible
or enrolment if they were aged 10–25 years at the time of ﬁrst
accination, HIV negative, not pregnant, had not had more than six
ifetime sexual partners, were free of obvious health problems as
stablished by medical history and examination, had no history of
eurologic disorders and were willing to use contraception or to
bstain from sex if sexually active for 30 days prior to vaccination2 (2014) 611– 617
and  for two  months after completion of vaccination. The enrolment
was age-stratiﬁed, with one-third of participants in the 10–14 years
age-stratum and the remainder in the 15–25 years age-stratum.
Study  procedures for the HPV 021 trial have been described in
detail elsewhere [12]. In brief, the HPV vaccine and placebo were
administered intramuscularly into the deltoid muscle of the non-
dominant arm at the Month 0 visit and again at Month 1 and Month
6 visits. Sociodemographic characteristics were collected at Month
0 in face-to-face interviews using standardized questionnaires.
Blood samples were collected at Months 0, 2, 7 and 12 to evaluate
antibody responses against HPV-16 and HPV-18 by enzyme-linked
immunosorbent assay (ELISA). In order to test for helminth infec-
tion and malaria parasitaemia at Month 7, participants provided
(i) a blood sample for the diagnosis of malaria, (ii) a ﬁrst void urine
sample for the diagnosis of Schistosoma haematobium and (iii) three
separate stool samples (during the week following the Month 7
visit) for the diagnosis of Schistosoma mansoni, Ancylostoma duo-
denale (hookworm), Strongyloides stercoralis, Ascaris lumbricoides,
Trichuris trichiura and Taenia spp. Participants who tested positive
for malaria or helminth infections were provided with treatment
by study clinicians at a subsequent study visit.
2.1. Laboratory testing
2.1.1.  Malaria
Pairs of thick and thin peripheral blood ﬁlms from each patient
were stained with Giemsa stain in Mwanza, and examined by light
microscopy at NIMR in Mwanza, and conﬁrmed at LSHTM. Each
thick ﬁlm was  scanned under oil immersion for at least 5 min  and
the presence of asexual malaria parasites or sexual gametocytes
was recorded. Where parasites were seen, the number per 200
white blood cells (WBC) on the thick ﬁlm was counted and mul-
tiplied by 40 to give number of parasites per microliter (parasite
density, assuming 8000 WBC  per L as per World Health Orga-
nization recommendations for Africa) [13]. In thin ﬁlms, parasite
detection (where possible) and species conﬁrmation was done by
scanning for a similar duration.
2.1.2.  Helminths
A  10 mL  aliquot from each urine sample was  ﬁltered through
25 mm,  12 m Millipore ﬁlters on Swinnex ﬁlter holders. After ﬁl-
tration, the ﬁlter was placed onto a glass slide using blunt forceps
adding a drop of saline and a glass coverslip. The ﬁlter was then
examined at the NIMR laboratory under light microscopy for the
eggs of S. haematobium.
Stool  samples were examined at the NIMR laboratory for
quantitative egg counts for S. mansoni, hookworm, S stercoralis,
A. lumbricoides, T. trichiura and Taenia spp. using the Kato-Katz
method [14,15]. The stool samples were ﬁrst homogenised by pass-
ing through a sieve, and then a 41.7 mg  template was used. The
faecal portion was covered with a cellophane square that had been
soaked in malachite green and glycerol. The sample was  exam-
ined immediately and then again after 24 h. Eggs were counted and
expressed as eggs per gram of faeces. For quality control, a ran-
dom sample of 10% of positive and negative stool slides were sent
to the Uganda Virus Research Institute/Medical Research Council
laboratories in Entebbe for repeat Kato-Katz testing.
In  addition, charcoal culture was used to conﬁrm S. stercoralis in
a subset of samples. Approximately 50 mg  of unﬁxed fresh faeces
were mixed with distilled water in a 20 mL  universal tube [16]. To
this suspension an equal volume of granulated hardwood charcoal
was added. After mixing, the suspension was  placed over a wet
disc of ﬁlter paper in a petri dish and stored in the dark at room
temperature. The petri dishes were observed daily for the presence
cine 3
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f larvae for a week under a dissection microscope, adding water
o the ﬁlter paper as needed.
.1.3.  HPV immunogenicity
As  part of the HPV 021 trial, serological assays for immuno-
enicity were performed at a GSK laboratory in Belgium. ELISA was
sed to determine antibodies to HPV-16 and HPV-18 as described
reviously [17]. As there are no established immunological cor-
elates of protection for HPV-16 or HPV-18, immunogenicity was
etermined in terms of seroconversion rates and geometric mean
ntibody titres (GMTs). Seropositivity was deﬁned as an antibody
itre greater than or equal to the assay threshold of 8 ELISA units
EU)/mL for HPV-16 and 7 EU/mL for HPV-18 [17].
.2.  Analyses
Data were double entered and veriﬁed in DMSys® (SigmaSoft
nternational) and analysed using STATA11.0 (StataCorp LP; College
tation, Texas, USA). Sociodemographic characteristics of partic-
pants attending the Month 7 visit were tabulated by infection
tatus and overall. The prevalence of malaria parasitaemia and each
elminth infection at Month 7 was tabulated by age group and
verall. Helminth infection intensities were classiﬁed into light,
oderate and heavy, according to WHO  guidelines [18]. For each
ndividual, the arithmetic mean of the helminth species-speciﬁc
gg counts from the Kato-Katz thick stool smears was  calculated
nd multiplied by 24, to obtain the eggs per gram of faeces (EPG).
he upper limits of light and moderate infections were 100 and
00 EPG for S. mansoni; 2000 and 4000 EPG for hookworm; 1000
nd 10,000 EPG for T. trichiura and 5000 and 50,000 EPG for A. lum-
ricoides, respectively. For S. haematobium, egg counts from urine
ere classiﬁed into two categories only, light (<50 eggs/10 mL  of
rine) and heavy (≥50 eggs/10 mL  of urine or visible haematuria).
here were too few participants in the vaccine-arm who  were
o-infected with both malaria and helminth infections (n = 8), or
ultiple helminth infections (n = 6) to examine the relationship
etween co-infection and HPV immunogenicity.
Because the anti-HPV-16 and HPV-18 IgG antibody concentra-
ions showed skewed distributions, HPV antibody results were
ransformed as log10 (IgG concentration). Geometric mean titres
GMT, EU/mL) and 95% conﬁdence intervals (CI) were calculated.
The  analysis of HPV vaccine antibody response, and malaria and
elminth infection was restricted to participants in the vaccine-
rm who attended the Month 7 visit (n = 195) or the Month 12
isit (n = 196) and had immunogenicity results. Box plots were used
o graphically examine the distribution of raw antibody responses
y malaria and helminth infection status. Linear regression was
sed to compare mean log-transformed IgG antibody between
articipants with and without any helminth infection, and with
nd without malaria. Regression coefﬁcients and conﬁdence lim-
ts were back-transformed to express results as ratios of geometric
eans (GMR). These analyses controlled for potential confound-
ng by age of participants, and number of vaccine doses received.
nalyses of malaria and HPV vaccine antibody response controlled
or presence of any helminth infection. Similarly, the analyses of
elminth infection and HPV vaccine antibody response controlled
or malaria parasitaemia. There were insufﬁcient data to examine
ssociations with speciﬁc helminth infections.
. Results
.1. Cohort screening, enrolment and follow-upIn total 587 participants attended the screening visit, and 334
ere enrolled in the HPV 021 trial. Of these, 221 participants were
andomized to the vaccination arm and 113 to the placebo-arm.2 (2014) 611– 617 613
Overall,  298 (89%) participants attended the Month 7 visit (90 and
88% in the vaccine and placebo arms, respectively) and 308 (92%)
attended the Month 12 visit (93 and 90% in the vaccine and placebo
arms, respectively). The most common reason for discontinuation
was withdrawal of consent (4%). The majority (96%) of participants
received all three vaccine or placebo doses (Table 1); number of
doses received did not differ substantially between participants in
the vaccine and placebo arms or between those with and without
malaria and/or helminth infections (Table 1) in either trial arm.
All  participants were of African origin and were HIV-
seronegative at baseline. The median age of participants was  18
years (IQR = 13–19). More than three-quarters of participants (82%)
were currently students. Most (89%) participants were single.
Approximately one-third (37%) of participants lived in houses con-
structed from cement blocks, and 40% lived in homes constructed
from mud  bricks (Table 1). As previously reported, sociodemo-
graphic characteristics did not differ by vaccine-arm [12].
3.2.  Prevalence of malaria and helminths at Month 7
At  Month 7, approximately one-third (38.1%) of participants
tested positive for either malaria parasitaemia or helminth infec-
tion. The prevalence of malaria parasitaemia in the entire cohort
was 10.2% (Table 2) and in the vaccinated cohort was 10.5%. The
prevalence of any helminth infection was 30.4% in the entire cohort
(Table 2), and 31.6% in the vaccinated cohort. S. mansoni was  the
most commonly detected helminth, found in one-quarter of partic-
ipants (24.0%), followed by hookworm (5.7%). S. haematobium was
rare; only two (0.7%) participants tested positive. The prevalence of
malaria parasitaemia was  somewhat higher in younger participants
(Table 2), although there was not strong evidence of a difference
(p = 0.24).
Three quarters (77.9%) of S. mansoni infections were light infec-
tions, 17.6% were moderate and 4.4% were heavy. Of the two S.
haematobium infections, one was light and one was  heavy. All
(100%) of the hookworm, A. lumbricoides, T. trichiura and Taenia spp.
infections were categorized as light infections.
3.3. Geometric mean titres for HPV-16/18 antibody response
As  previously reported, all initially seronegative participants in
the vaccinated cohort seroconverted for anti-HPV-16 and -18 anti-
bodies, and remained seropositive up to Month 7. At Month 12, all
initially seronegative participants in the vaccine group remained
seropositive for anti-HPV-16, and all except one (13-year-old girl)
remained seropositive for anti-HPV-18 [12]. Four participants had
missing antibody results at Month 7, but were seropositve for anti-
HPV-16 and -18 antibodies at Month 12.
HPV immunogenicity was high at Month 7 and Month 12.
Among the vaccinated cohort who  attended the Month 7 visit
and had antibody results (n = 195), the GMT  HPV-16 antibody
response at Month 7 was  10,786 EU/mL (95% CI 9126–12,747),
and the GMT  HPV-18 antibody response was 3701 EU/mL (95% CI
3156–4340) (Table 3). As previously reported, HPV-16/18 serosta-
tus at enrolment (prior to vaccination) did not inﬂuence GMTs at
Month 7 or Month 12 [12]. GMT  HPV-16 and HPV-18 antibody
responses at Month 7 were at least 2 fold higher in 10–14-year-
olds (19,374 EU/mL, 95% CI 16,600–22,611 and 5723 EU/mL, 95%
CI 4790–6839, respectively) than in 15–25-year-olds (7770 EU/mL,
95% CI 6188–9755 and 2900 EU/mL, 95% CI 2333–3605, respec-
tively, P < 0.001).
Antibody responses to HPV-16/18 among 107 vaccine-arm par-
ticipants without helminths or malaria parasitaemia were high.
The GMT  HPV-16 antibody response among helminth and malaria
uninfected 10–14-year-olds at Month 7 (N = 40) was  18,248 EU/mL
(95% CI 14,742–22,587), and for 15–25-year-olds (N = 67) was
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Table  1
Characteristics of cohort attending for Month 7 visit.
By infection statusa (N = 273)
No infection
(N  = 169)
n (%)
Any helminthb (N = 86)
n (%)
Malariab (N = 29)
n  (%)
Totalc (N = 298)
n  (%)
Age group (years)
10–14  62 (36.7) 25 (29.1) 14 (48.3) 107 (35.9)
15–19  74 (43.8) 48 (55.8) 10 (34.5) 138 (46.3)
20–25  33 (19.5) 13 (15.1) 5 (17.2) 53 (17.8)
Tribed
Sukuma 57 (33.9) 30 (34.9) 9 (31.0) 97 (32.7)
Non-sukuma  111 (66.1) 56 (65.1) 20 (69.0) 200 (67.3)
Religiond
Catholic 79 (47.3) 41 (47.7) 15 (51.7) 137 (46.3)
Other  christian 48 (28.7) 22 (25.6) 7 (24.1) 81 (27.4)
Muslim  40 (24.0) 23 (26.7) 7 (24.1) 78 (26.4)
Education  leveld
Less than primary 47 (28.0) 27 (31.4) 11 (37.9) 87 (29.3)
Primary  39 (23.2) 20 (23.3) 7 (24.1) 70 (23.6)
Secondary  77 (45.8) 37 (43.0) 11 (37.9) 129 (43.4)
Above  secondary 5 (3.0) 2 (2.3) 0 (-) 11 (3.7)
Marital  statusd
Single 149 (88.7) 75 (87.2) 25 (86.2) 265 (89.2)
Married  19 (11.3) 11 (12.8) 3 (10.3) 31 (10.4)
Divorced/separated 0 0 1 (3.5) 1 (0.3)
Occupationd
Student 137 (82.5) 67 (77.9) 24 (82.8) 243 (82.4)
Manual/clerical/other 12 (7.2) 7 (8.1) 3 (10.3) 21 (7.1)
Housewife/unemployed 17 (10.2) 12 (14.0) 2 (6.9) 31 (10.5)
Housing  constructiond
Cement blocks 68 (41.0) 27 (31.4) 10 (34.5) 108 (36.6)
Mud  bricks 64 (38.6) 34 (39.5) 12 (41.4) 118 (40.0)
Burnt  bricks 26 (15.7) 14 (16.3) 6 (20.7) 50 (16.9)
Other  8 (4.8) 11 (12.8) 1 (3.5) 19 (6.4)
Vaccine  doses received
Three  160 (94.7) 85 (98.8) 29 (100) 287 (96.3)
Less  than three 9 (5.3) 1 (1.2) 0 11 (3.7)
a Among 273 participants with complete data on all infections.
b Includes 11 participants who were positive for both helminth and malaria infection.
c Among 298 participants who attended the 7 month visit.
d Missing data on tribe, education and marital status for 1 participant. Missing data on religion for 2 participants. Missing data on occupation and housing construction for
3  participants.
Table 2
Prevalencea of helminths and malaria infection at Month 7, by age group and overall.
10–14 years (N = 107)n (%) 15–19 years (N = 138)n (%) 20–25 years (N = 53)n (%) All ages (N = 298)n (%)
S. mansonib 20 (19.6) 42 (32.1) 6 (12.0) 68 (24.0)
Hookwormb 2 (2.0) 7 (5.3) 7 (14.0) 16 (5.7)
S. stercoralisb 0 0 0 0
A.  lumbricoidesb 2 (2.0) 0 0 2 (0.7)
T. trichiurab 2 (2.0) 1 (0.8) 3 (6.0) 6 (2.1)
Taenia spp.b 0 0 1 (2.0) 1 (0.4)
S. haematobium 1 (0.9) 1 (0.7) 0 2 (0.7)
Any helminthc 25 (24.5) 48 (36.6) 13 (26.0) 86 (30.4)
Malariad 14 (14.1) 10 (7.5) 5 (9.6) 29 (10.2)
Number of infectionse
None 62 (64.6) 74 (57.8) 33 (67.4) 169 (61.9)
1 27 (28.1) 47 (36.7) 10 (20.4) 84 (30.8)
2 6 (6.3) 7 (5.5) 6 (12.2) 19 (7.0)
3 1 (1.0) 0  0 1 (0.4)
a Prevalence of each infection is among those without missing data for that organism.
b Missing helminth results for 5 participants in 10–14 years age group, 7 in the 15–19 years age group and 3 in the 20–25 years age group.
c Among 283 participants with complete data on all helminths.
d Missing malaria results from 8 participants in the 10–14 years age group, 4 particpants in the 15–19 years age group and 1 participant in the 20–25 years age group.
e Among 273 participants with complete data on all infections.
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Table  3
Antibody responses at Month 7 and at Month 12 in vaccinated participants by helminth infection and malaria infection status.
N Geometric mean titre
(EU/mL)  (95% CI)
Unadjusted geometric
mean  ratio (95% CI)
Adjusted geometric mean
ratioa (95% CI)
Month 7
HPV-16 IgG
Overall  195 10786 (9126–12747) – –
Any helminth
No  126 10492 (8445–13036) P = 0.27 P > 0.99
Yes  60 12761 (10269–15857) 1.22 (0.86–1.72) 1.00 (0.77–1.29)
Intensity of helminth infection
None  126 10492 (8445–13036) P = 0.48 P = 0.72
Light  50 12363 (9936–15383) 1.18 (0.81–1.71) 0.96 (0.73–1.26)
Moderate/heavy 10 14946 (6442–34679) 1.42 (0.69–2.95) 1.20 (0.71–2.03)
Malaria
No 166 9750 (8082–11761) P = 0.01 P = 0.05
Yes  20 20357 (14430–28720) 2.09 (1.20–3.63) 1.47 (1.00–2.18)
HPV-18 IgG
Overall  195 3701 (3156–4340) – –
Any helminth
No  126 3513 (2880–4285) P  = 0.19 P = 0.64
Yes  60 4392 (3418–5643) 1.25 (0.90–1.75) 1.06 (0.82–1.38)
Intensity of helminth infection
None  126 3513 (2880–4285) P = 0.26 P = 0.35
Light  50 4129 (3162–5393) 1.18 (0.82–1.68) 1.00 (0.75–1.32)
Moderate/heavy 10 5973 (2689–13268) 1.70 (0.84–3.42) 1.46 (0.85–2.51)
Malaria
No 166 3434 (2873–4104) P  = 0.07 P = 0.42
Yes  20 5648 (3736–8538) 1.64 (0.97–2.80) 1.18 (0.79–1.76)
Month 12
HPV-16 IgG
Overall  196 2656 (2246–3140) – –
Any helminth
No  129 2613 (2124–3215) P = 0.64 P = 0.70
Yes  59 2843 (2171–3723) 1.09 (0.76–1.55) 0.94 (0.67–1.31)
Intensity of helminth infection
None  129 2617 (2129–3217) P = 0.67 P = 0.70
Light  49 2994 (2301–3895) 1.14 (0.78–1.67) 0.98 (0.69–1.40)
Moderate/heavy 10 2218 (745–6600) 0.85 (0.40–1.77) 0.75 (0.38–1.48)
Malaria
No 167 2461 (2039–2971) P = 0.05 P = 0.16
Yes  20 4335 (2890–6502) 1.76 (1.01–3.08) 1.43 (0.86–2.37)
HPV-18 IgG
Overall  196 986 (834–1166) – –
Any helminth
No  129 970 (781–1205) P = 0.71 P = 0.89
Yes  59 1038 (802–1344) 1.07 (0.74–1.54) 0.98 (0.69–1.38)
Intensity of helminth infection
None  129 973 (784–1207) P = 0.83 P = 0.85
Light  49 1076 (806–1436) 1.11 (0.75–1.63) 1.01 (0.70–1.47)
Moderate/heavy 10 880 (453–1712) 0.90 (0.42–1.93) 0.82 (0.41–1.66)
Malaria
No 167 952 (787–1151) P = 0.59 P = 0.79
Yes  20 1109 (764–1609) 1.16 (0.66–2.05) 0.93 (0.55–1.58)
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Ha Geometric mean ratio (GMR) for helminth infection adjusted for participant ag
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493 EU/mL (95% CI 4606–9153). Similarly, the GMT  HPV-18
ntibody response among helminth and malaria uninfected 10–14-
ear-olds at Month 7 was 5255 EU/mL (95% CI 4109–6720), and for
5–25-year-olds was 2479 EU/mL (95% CI 1807–3399).
There  was some evidence that participants with malaria parasi-
aemia at Month 7 had a higher GMT  HPV-16 and HPV-18 antibody
esponse (Table 3; Fig. 1). After controlling for age, number of vac-
ine doses received, and any helminth infection, participants with
vidence of malaria had a roughly 1.5 fold higher HPV-16 GMT
han participants without malaria (adjusted geometric mean ratio
GMR) = 1.47, 95% CI 1.00–2.18, P = 0.05). Participants with malaria
arasites had a 1.2 fold higher GMT  HPV-18 antibody response
t Month 7 compared to participants without malaria (adjusted
MR = 1.18, 95% CI 0.79–1.76, P = 0.42).
At the Month 12 visit, there was also some evidence that the
PV-16 GMT  antibody response was higher among participantsber of vaccine doses and malaria infection. GMR  for malaria infection adjusted for
with  malaria parasitaemia at Month 7, adjusting for age, number
of vaccine doses received, and any helminth infection (adjusted
GMR = 1.43, 95% CI 0.86–2.37, P = 0.16) (Table 3). There was no evi-
dence of a difference in HPV-18 GMT  antibody response at Month
12 between participants with malaria parasitaemia at Month 7
and those without (adjusted GMR  = 0.93, 95% CI 0.55–1.58, P = 0.79)
(Table 3).
At  Month 7 and Month 12, GMT  antibody responses were simi-
lar in participants with and without helminth infections (Table 3).
The GMR  for HPV-16 antibody response at Month 7, comparing
participants with and without helminth infection, was 1.00 (95%
CI 0.77–1.29, P > 0.99), after controlling for age, number of vac-
cine doses received and malaria parasitaemia (Table 3; Fig. 1).
The adjusted GMR  for HPV-18 antibody response comparing par-
ticipants with and without helminth infection was 1.06 (95%
CI 0.82–1.38, P = 0.64). Similar results were seen at Month 12.
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Fig. 1. Anti-HPV-16 (top) and HPV-18 (bottom) titre at 7 months after ﬁrst dose of
HPV vaccine in Tanzanian females aged 10–25 years, by helminth and malaria infec-
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lthough mean antibody response was highest in participants with
igher intensity helminth infections, there was no evidence of a
ignﬁcant difference (Table 3).
. Discussion
This is the ﬁrst study to examine the effect of malaria and
elminth infections on HPV vaccine antibody responses. The inci-
ence of cervical cancer is extremely high in many countries in
ub-Saharan Africa which are considering the implementation of
PV vaccination as a cervical cancer control strategy but which also
ave a high prevalence of endemic malaria and helminth infections.
hese infections can impact immune responses to vaccinations
3–9]. Reassuringly, we found no negative impact on the immune
esponse to the HPV-16/18 vaccine in the presence of these infec-
ions. The HPV-16/18 vaccine was highly immunogenic, especially
n younger girls, as previously observed [19].
We observed some evidence of an association between malaria
arasitaemia and a higher antibody response to the HPV-16/18
accine, which persisted adjusting for age. This association
ppeared weaker at Month 12 than Month 7 perhaps because
here was a longer interval between the timing of the malaria
nd helminth tests and the antibody data. There was no observed
ffect of helminth infection, or intensity of helminth infection, on
PV-16/18 antibody response. The mechanism and signiﬁcance
f the increase in HPV-16/18 GMTs among malaria infected2 (2014) 611– 617
individuals is unclear. It is possible that malaria may  induce a
broader spectrum antibody response than helminths, which may
potentiate the immune response to the HPV vaccine. We  were
unable to assess whether this observation was sustained beyond
12 months of follow-up.
As  in all observational studies, these ﬁndings may be distorted
by unmeasured confounders. We attempted to control for potential
confounding by age and number of vaccine doses received, which
produced little change in the effect estimates. This study also had a
small sample size, and a relatively small number of participants
with helminth and malaria infections. Results should therefore
be interpreted with caution. Sensitivity of the Kato-Katz method
in diagnosing helminth infections is relatively low, although we
attempted to increase the sensitivity by collecting 3 stool samples
from each participant [20,21]. Finally, infection diagnosed at one
point during follow-up will not be representative of infection sta-
tus at the time that earlier vaccine doses were administered. We
were therefore unable to measure the effect of earlier infections on
the response to the ﬁrst and second doses of vaccine.
Both animal and human studies indicate that parasitic infections
can impair long-term responses to vaccination [10,22]. Although
our results are encouraging up to one year post-vaccination,
because of the short-term nature of this study, our data do not
allow us to evaluate whether untreated malaria or helminth infec-
tions, repeated infections or co-infections may impair long-term
responses to the HPV vaccine. Longer-term follow-up of vac-
cinated cohorts and repeated cross-sectional surveys to assess
antibody response and helminth/malaria infections in communi-
ties are warranted.
In  summary, we found high HPV immunogenicity regardless of
the presence of malaria and helminth infections among young girls
and women  in Tanzania. There was some evidence of enhanced
antibody titres to HPV vaccine genotypes in participants with
malaria parasitaemia. Additional research on the impact of para-
sitic infection on the long-term duration of protection from HPV
vaccines is warranted.
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